or Try an Advanced Search...

    Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 1.40 -0.71% -0.01
    CRVS closed down 0.71 percent on Friday, April 19, 2024, on 26 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 6
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CRVS trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness -0.71%
    Wide Bands Range Expansion -0.71%
    Lower Bollinger Band Touch Weakness -0.71%
    Oversold Stochastic Weakness -0.71%
    Lower Bollinger Band Walk Weakness 2.94%
    Older End-of-Day Signals for CRVS ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    Possible Inside Day about 6 hours ago
    Up 1% about 9 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    Down 3% about 10 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CRVS Chart by TradingView
    Basic chart:

    Profile

    Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73

    Is CRVS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 17 Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
    Apr 9 Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
    Apr 1 Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
    Mar 22 Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
    Mar 21 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript
    Mar 20 Q4 2023 Corvus Pharmaceuticals Inc Earnings Call
    Mar 20 Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
    Mar 19 Corvus Pharmaceuticals GAAP EPS of -$0.14 misses by $0.01
    Mar 19 Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    Mar 13 Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
    See more CRVS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.19
    52 Week Low 0.9777
    Average Volume 223,555
    200-Day Moving Average 1.86
    50-Day Moving Average 1.95
    20-Day Moving Average 1.64
    10-Day Moving Average 1.51
    Average True Range 0.14
    RSI (14) 29.08
    ADX 44.29
    +DI 5.29
    -DI 25.99
    Chandelier Exit (Long, 3 ATRs) 1.56
    Chandelier Exit (Short, 3 ATRs) 1.72
    Upper Bollinger Bands 1.96
    Lower Bollinger Band 1.32
    Percent B (%b) 0.12
    BandWidth 38.67
    MACD Line -0.15
    MACD Signal Line -0.13
    MACD Histogram -0.018
    Fundamentals Value
    Market Cap 68.65 Million
    Num Shares 49 Million
    EPS -0.64
    Price-to-Earnings (P/E) Ratio -2.19
    Price-to-Sales 0.00
    Price-to-Book 2.44
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.52
    Resistance 3 (R3) 1.52 1.48 1.50
    Resistance 2 (R2) 1.48 1.45 1.48 1.49
    Resistance 1 (R1) 1.44 1.43 1.44 1.44 1.49
    Pivot Point 1.40 1.40 1.40 1.40 1.40
    Support 1 (S1) 1.36 1.37 1.36 1.36 1.31
    Support 2 (S2) 1.32 1.35 1.32 1.31
    Support 3 (S3) 1.28 1.32 1.30
    Support 4 (S4) 1.28